Neurocrine biosciences announces fda approval of crenessity™ (crinecerfont), a first-in-class treatment for children and adults with classic congenital adrenal hyperplasia

Crenessity, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (cah) community, offers a paradigm-shifting treatment approach fda approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic cah crenessity is expected to be commercially available in approximately one week rare pediatric disease priority review voucher granted in connection with approval san diego , dec. 13, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the u.s. food and drug administration has approved crenessity™ (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (cah), a rare, serious and lifelong genetic condition involving the adrenal glands. crenessity, a potent and selective oral corticotropin-releasing factor type 1 receptor (crf1) antagonist, is the first and only classic cah treatment that directly reduces excess adrenocorticotropic hormone (acth) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction.
NBIX Ratings Summary
NBIX Quant Ranking